A Single-arm Exploratory Study of Neoadjuvant Therapy
Status:
Not yet recruiting
Trial end date:
2025-12-30
Target enrollment:
Participant gender:
Summary
Neoadjuvant EGFR TKI therapy targeting EGFR mutation has some problems failure to fulfill
clinical requirements such as low MPR rate, tissue fibrosis and other major surgical impacts
and unmet clinical needs.This study hypothesized that Tisleizumab combined with chemotherapy
in the neoadjuvant treatment of stage II-IIIA non-squamous NSCLC with EGFR-mutant PD-L1
expression greater than or equal to 1% could significantly improve the pathological response
rate after neoadjuvant therapy, improve the surgical complete resection rate, reduce
perioperative complications and do not increase the surgical difficulty.In this study,
biomarker analysis is going to explore the possible direction of neoadjuvant therapy
population screening, and to explore a possible method for the efficacy and safety of
neoadjuvant immunotherapy in clinical stage II-IIIA non-squamous non-small cell lung cancer
with EGFR mutation and expression of PD-L1.